Trial Profile
A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Efineptakin alfa (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide
- Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-899
- Sponsors Genexine
- 08 Jun 2023 Status changed from active, no longer recruiting to completed.
- 25 Nov 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 25 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2023.